{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T10:23:53Z","timestamp":1779186233353,"version":"3.51.4"},"reference-count":36,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"unspecified","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772991, 81772884, and 81730081"],"award-info":[{"award-number":["81772991, 81772884, and 81730081"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972640"],"award-info":[{"award-number":["81972640"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273051"],"award-info":[{"award-number":["82273051"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The biological significance of MAF1, a tumor suppressor, in carcinogenesis and immune response of hepatocellular carcinoma (HCC) remains unreported. Understanding the underlying mechanisms by which MAF1 enhances anti-tumor immunity in HCC is crucial for developing novel immunotherapy strategies and enhancing clinical responses to treatment for patients with HCC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Mice were subjected to hydrodynamic tail vein injections of transposon vectors to overexpress AKT\/NRas, or c-Myc, with or without wild-type (WT) or mutant-activated (\u22124A) MAF1, or short-hairpin MAF1 (shMAF1). Liver tissues and tumors were harvested and analyzed using histology, immunohistochemistry, immunoblotting, quantitative reverse-transcription PCR, and flow cytometry. MAF1 was overexpressed or knocked down in HCC cells via lentiviral transfection. Cell lines were analyzed using RNA sequencing, immunoblotting, dual luciferase reporter, and chromatin precipitation assays.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Both MAF1-WT and MAF1-4A proteins significantly inhibit hepatocarcinogenesis in mice, with the mutant form exhibiting a stronger suppressive effect. Although MAF1 knockdown alone does not induce abnormalities in the mouse liver, it accelerates c-Myc-induced carcinogenesis. Our results provide the first in vivo evidence that MAF1 plays a tumor suppressor role by activating PTEN to suppress the AKT-mammalian target of rapamycin signaling pathway during hepatocarcinogenesis in physiologically relevant tumor models. More importantly, we found that MAF1 not only enhances the intratumoral infiltration of CD8<jats:sup>+<\/jats:sup> T cells by increasing CXCL10 secretion but also enhances their functional activity by inhibiting PDL1 transcription in mouse liver cancer, which were confirmed in human HCC or in vitro experiments. Furthermore, PDL1 overexpression accelerates mouse hepatocarcinogenesis by antagonizing the tumor-suppressive role of MAF1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our study uncovers a novel anti-tumor immunity of MAF1 in hepatocarcinogenesis and human HCC. These findings suggest that the stimulated MAF1 could potentially improve immunotherapy in combination with immune checkpoint inhibitors in HCC patients, especially in those with an absence of T cells in HCC tissues.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2024-009656","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T23:45:30Z","timestamp":1736639130000},"page":"e009656","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["MAF1 inhibits hepatocarcinogenesis by fostering an immunostimulatory tumor microenvironment"],"prefix":"10.1136","volume":"13","author":[{"given":"Di","family":"Cao","sequence":"first","affiliation":[{"name":"State Key Laboratory of Oncology in South China, and Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China"},{"name":"Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue-Ning","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, and Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Yue","family":"Sun","sequence":"additional","affiliation":[{"name":"College of Biological and Pharmaceutical Engineering, West Anhui University, Lu'an, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haojiang","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, and Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Health Technology and Informatics, Hong Kong Polytechnic University University Learning Hub, Kowloon, Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Feng","family":"Zhou","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, and Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei-Yin","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, and Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo-Cheng","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, and Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0017-8194","authenticated-orcid":false,"given":"Shi-Juan","family":"Mai","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, and Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6728-4376","authenticated-orcid":false,"given":"Hui-Yun","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, and Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"key":"2025100311485827000_13.1.e009656.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30010-2"},{"key":"2025100311485827000_13.1.e009656.2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4254\/wjh.v8.i9.421","article-title":"New advances in hepatocellular carcinoma","volume":"8","author":"Pascual","year":"2016","journal-title":"World J Hepatol"},{"key":"2025100311485827000_13.1.e009656.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"2025100311485827000_13.1.e009656.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70285-7"},{"key":"2025100311485827000_13.1.e009656.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32453-9"},{"key":"2025100311485827000_13.1.e009656.6","article-title":"Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors","volume":"11","author":"Park","year":"2022","journal-title":"Biol (Basel)"},{"key":"2025100311485827000_13.1.e009656.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.01.031"},{"key":"2025100311485827000_13.1.e009656.8","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.21.15.5031-5040.2001"},{"key":"2025100311485827000_13.1.e009656.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(02)00787-6"},{"key":"2025100311485827000_13.1.e009656.10","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00319-10"},{"key":"2025100311485827000_13.1.e009656.11","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2009.179"},{"key":"2025100311485827000_13.1.e009656.12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1113311109"},{"key":"2025100311485827000_13.1.e009656.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004789","article-title":"Maf1 is a novel target of PTEN and PI3K signaling that negatively regulates oncogenesis and lipid metabolism","volume":"10","author":"Palian","year":"2014","journal-title":"PLoS Genet"},{"key":"2025100311485827000_13.1.e009656.14","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28507"},{"key":"2025100311485827000_13.1.e009656.15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1904396116"},{"key":"2025100311485827000_13.1.e009656.16","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1097\/HEP.0000000000000024","article-title":"5S rRNA pseudogene transcripts are associated with interferon production and inflammatory responses in alcohol-associated hepatitis","volume":"77","author":"Wu","year":"2023","journal-title":"Hepatology"},{"key":"2025100311485827000_13.1.e009656.17","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25776"},{"key":"2025100311485827000_13.1.e009656.18","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.12.006"},{"key":"2025100311485827000_13.1.e009656.19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24736"},{"key":"2025100311485827000_13.1.e009656.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2013.12.002"},{"key":"2025100311485827000_13.1.e009656.21","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.071639"},{"key":"2025100311485827000_13.1.e009656.22","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29183"},{"key":"2025100311485827000_13.1.e009656.23","doi-asserted-by":"crossref","unstructured":"Alspach E , Lussier DM , Schreiber RD . Interferon Gamma and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity, 11. Cold Spring Harb Perspect Biol, 2019.","DOI":"10.1101\/cshperspect.a028480"},{"key":"2025100311485827000_13.1.e009656.24","doi-asserted-by":"crossref","first-page":"1166951","DOI":"10.3389\/fimmu.2023.1166951","article-title":"Aerosolized miR-138-5p and miR-200c targets PD-L1 for lung cancer prevention","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"2025100311485827000_13.1.e009656.25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.679324","article-title":"The Enhanced Inhibitory Effect of Estrogen on PD-L1 Expression Following Nrf2 Deficiency in the AOM\/DSS Model of Colitis-Associated Cancer","volume":"11","author":"Kang","year":"2021","journal-title":"Front Oncol"},{"key":"2025100311485827000_13.1.e009656.26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.canlet.2021.05.007","article-title":"Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation","volume":"513","author":"Ke","year":"2021","journal-title":"Cancer Lett"},{"key":"2025100311485827000_13.1.e009656.27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI63212"},{"key":"2025100311485827000_13.1.e009656.28","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1002\/hep.26411","article-title":"On the role of notch1 and adult hepatocytes in murine intrahepatic cholangiocarcinoma development","volume":"58","author":"Evert","year":"2013","journal-title":"Hepatology"},{"key":"2025100311485827000_13.1.e009656.29","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17111942","article-title":"Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment","volume":"17","author":"Cui","year":"2016","journal-title":"Int J Mol Sci"},{"key":"2025100311485827000_13.1.e009656.30","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26731"},{"key":"2025100311485827000_13.1.e009656.31","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24149"},{"key":"2025100311485827000_13.1.e009656.32","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1002\/hep.31600","article-title":"Lysyl Oxidase-Like 4 Fosters an Immunosuppressive Microenvironment During Hepatocarcinogenesis","volume":"73","author":"Tan","year":"2021","journal-title":"Hepatology"},{"key":"2025100311485827000_13.1.e009656.33","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327924"},{"key":"2025100311485827000_13.1.e009656.34","doi-asserted-by":"crossref","first-page":"28453","DOI":"10.18632\/oncotarget.4601","article-title":"Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials","volume":"6","author":"Subbiah","year":"2015","journal-title":"Oncotarget"},{"key":"2025100311485827000_13.1.e009656.35","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11266"},{"key":"2025100311485827000_13.1.e009656.36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.1999.tb00763.x"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-009656","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T18:49:04Z","timestamp":1759517344000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-009656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,11]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/jitc-2024-009656"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-009656","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}